Imagin Medical names Chris Bleck to its board
Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart:DPD2) named Chris Bleck to its board.
Mr. Bleck has more than three decades of experience, including leading or being integrally involved with multiple clinical development programs, commercial product launches, public financings, licensing transactions, and mergers and acquisitions.
Most recently, he served as the COO of OvaScience. His earlier experience includes senior management roles with Cytyc, Intact Medical and Incept BioSystems. Mr. Bleck began his career at Abbot Laboratories, where he held progressive positions over 18 years, including corporate VP of pediatric products and president of Abbott Canada.
Dr. Robin Atlas, chairman of Imagin, said Mr. Bleck has extensive executive leadership experience, playing a critical role in developing corporate strategy and managing operations for both emerging and large companies in the global healthcare industry.
“The recent submission of a pre-submission package marked the initiation of the FDA process for Imagin’s i/Blue Imaging System, and Chris’ diverse background working with companies in the medical device, diagnostic, nutrition and pharmaceutical industries should prove to be a tremendous asset to our board and to our shareholders as we move forward,” he added.